buPROPion Hydrochloride Extended-Release Tablets, USP (XL) 150mg, 30-count bottles, Rx Only, Manu...

FDA Recall #D-0222-2024 — Class II — December 29, 2023

Recall #D-0222-2024 Date: December 29, 2023 Classification: Class II Status: Ongoing

Product Description

buPROPion Hydrochloride Extended-Release Tablets, USP (XL) 150mg, 30-count bottles, Rx Only, Manufactured for: Rising Pharma Holdings, Inc. East Brunswick, NJ 08816 Manufactured by: Graviti Pharmaceuticals Pvt. Ltd. Telangana - 502307, INDIA, NDC 16571-862-03

Reason for Recall

Presence of Foreign Tablets/Capsules

Recalling Firm

Rising Pharma Holding, Inc. — East Brunswick, NJ

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

47,976 bottles

Distribution

Nationwide within the United States

Code Information

Lot #: BPA123098A, Exp. Date 06/2025

Status

Ongoing

Voluntary / Mandated

Voluntary: Firm initiated